Prospect of Ertapenem in Bangladesh Pharmaceutical Market

Abstract

Ertapenem is a sterile, synthetic, parenteral, I-~ methyl-carbapenem that is structurally related to beta-lactam antibiotics. Ertapenem, a Group 1 carbapenem, is most recently introduced into the market and cover both Gram positive and Gram negative pathogens. Here the objective is to find the characteristics of ertapenem in the treatment of complicated infectious diseases and establish demonstrated safety profile and clinical efficacy of ertapenem against complicated diseases. This report is fully based on secondary data which I have collected from many journals, IMS, MIMS, browsing different web sites. From this research it was found that ertapenem shows excellent success in complicated infectious diseases. By doing market strategy regarding IMS data it is assume that if it is launched in the market the total market size will be 31,087,084 within 1-2 years which makes the drug feasible in the market.